European Interventional Radiological Society Enrols First Patient in New SIR Spheres® (Yttrium-90 resin microspheres) Registry

Monday 19 January 2015
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for SIR-Spheres Therapy (CIRT). New registry will gather data on patients with inoperable liver tumours treated with SIR-Spheres® Y-90 resin microspheres at specialist hospitals across Europe.

Bonn, Germany, 19 January 2015 -- CIRSE today announced that the first patient has been enrolled in a new registry designed to capture information on patients with inoperable liver tumours who are treated  with  SIR-Spheres  Y-90  resin  microspheres,  the  most  commonly  used  form  of  selective internal radiation therapy or SIRT.  The CIRSE Registry for SIR-Spheres Therapy (CIRT) was developed by the Society in collaboration with Sirtex Medical Limited, the manufacturer of SIR-Spheres Y-90 resin microspheres.

”CIRSE is pleased to have developed the CIRT registry, which we believe will help the doctors who administer SIR-Spheres therapy to gain added insight about those patients with inoperable liver tumours who are most likely to benefit from this treatment,” stated Professor José Ignacio Bilbao, speaking on behalf of CIRSE as Chairman of the CIRT Steering Committee.  ”Our goal is to enter treatment data on over 500 patients a year from more than 20 specialist European hospitals into the new CIRT registry,” said Professor Bilbao, who is also head of interventional radiology at Clínica Universidad de Navarra in Pamplona, Spain.

”Sirtex believes that the comprehensive SIR-Spheres microspheres registry that CIRSE has just inaugurated will help inform future clinical decision-making by providing interventional radiologists with new information about those patients who are most likely to benefit from this form of therapy. We think this may be a useful step to improving hope for people with inoperable liver tumours,” said Nigel Lange, CEO of Sirtex Medical Europe GmbH.

SIR-Spheres Y-90 resin microspheres, the lead product of Sirtex Medical Limited, is the only product used for Selective Internal Radiation Therapy (SIRT) that has been recommended in the latest European Society of Medical Oncology (ESMO) clinical guidelines for treating metastatic colorectal cancer (mCRC).1

In April 2013, Sirtex announced that it had completed recruitment of patients for SIRFLOX, a 500- patient randomised clinical study that compares the use of SIR-Spheres Y-90 resin microspheres in combination with current first-line chemotherapy to current chemotherapy alone in the treatment of patients recently diagnosed with inoperable mCRC, which is much earlier in the treatment paradigm. Data from SIRFLOX are expected later in 2015.

About SIR-Spheres Y-90 Resin Microspheres

SIR-Spheres  Y-90  resin  microspheres  are a medical device  used  in interventional  oncology  (also known as SIRT or radioembolisation), a proven technology for inoperable liver tumours that delivers substantial, targeted doses of radiation directly to the cancer.  In a minimally invasive treatment, millions of SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing the adjacent healthy liver tissue.

Manufactured by Sirtex Medical Limited, SIR-Spheres microspheres are approved in the European Union (CE Mark) and many other countries for the treatment of liver tumours that are unable to be removed through surgery.  Available at more than 700 treatment centres, over 45,000 doses of SIR- Spheres microspheres have been supplied worldwide.

®SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd.


  1. 1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol 2014; 25 (Suppl 3): iii1-iii9.


For further information on the CIRT study, please contact:

Niels de Jong; CIRSE, +43 1 904 2003 47, or visit


# 975-E-0115

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage